ALNA - Allena Pharma provides update on clinical development programs: ALLN-346 and ALLN-177

Allena Pharmaceuticals ([[ALNA]]) provides progress updates on its clinical programs: ALLN-346 in development for the treatment of patients with hyperuricemia and gout in the setting of chronic kidney disease ((CKD)) and reloxaliase (ALLN-177) in development for the treatment of patients with enteric hyperoxaluria. ALLN-346: Phase 1b Study Results and Planned Phase 2A Program The Company recently completed a Phase 1b multiple ascending dose study of ALLN-346 which included 18 healthy volunteers. ALLN-346 was well tolerated with no significant safety signals and serious adverse events. The Company is preparing to initiate two Phase 2a studies to obtain initial bioactivity data and additional safety data for ALLN-346 in patients with hyperuricemia and gout during Q3 2021. Initial results from the Phase 2a program are expected during Q4 2021. An inpatient study (Study 201) is planned to initially enroll 12 patients with hyperuricemia for a period of one week. An outpatient study (Study 202)

For further details see:

Allena Pharma provides update on clinical development programs: ALLN-346 and ALLN-177